Ampicillin Sodium And Sulbactam Sodium Injection, Powder, For Solution
NDC Package 83270-308-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Ampicillin Sodium And Sulbactam Sodium (ampicillin sodium, sulbactam sodium) injection is ampicillin and Sulbactam for Injection, USP, is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below.Skin and Skin Structure Infectionscaused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli, *Klebsiella spp.*(including K. This formulation utilizes a injection, powder, for solution delivery system. Marketed by Onesource Specialty Pharma Limited, this product is identified by NDC 83270-308 and is authorized under FDA application ANDA202197.

Identification & Billing

NDC Package Code
83270-308-01
Package Description
1 BOTTLE in 1 CARTON / 15 g in 1 BOTTLE
Product Code
83270-308
11-Digit Billing Format
83270030801
RxNorm Crosswalk
  • RxCUI: 240984 - ampicillin 100 MG / sulbactam 50 MG in ML Injectable Solution
  • RxCUI: 240984 - ampicillin 100 MG/ML / sulbactam 50 MG/ML Injectable Solution
  • RxCUI: 240984 - ampicillin (as ampicillin sodium) 10 GM / sulbactam (as sulbactam sodium) 5 GM per 100 ML Injectable Solution
  • RxCUI: 240984 - ampicillin (as ampicillin sodium) 100 MG/ML / sulbactam (as sulbactam sodium) 50 MG/ML Injectable Solution

Clinical Specifications

Proprietary Name
Ampicillin Sodium And Sulbactam Sodium
Non-Proprietary Name
Ampicillin Sodium, Sulbactam Sodium
Substance Name
Ampicillin Sodium; Sulbactam Sodium
Dosage Form
Injection, Powder, For Solution - A sterile preparation intended for reconstitution to form a solution for parenteral use.
Administration Route
  • Intramuscular - Administration within a muscle.
  • Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
Pharmacologic Class
Usage Information
Ampicillin and Sulbactam for Injection, USP, is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below.Skin and Skin Structure Infectionscaused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli, *Klebsiella spp.*(including K. pneumoniae*), Proteus mirabilis,*Bacteroides fragilis, *Enterobacter spp., *and Acinetobacter calcoaceticus. *NOTE: For information on use in pediatric patients see PRECAUTIONS–Pediatric Use and CLINICAL STUDIES sections. Intra-Abdominal Infectionscaused by beta-lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. pneumoniae*), Bacteroides spp. (including B. fragilis), and Enterobacter spp.* Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli,* and Bacteroides spp.* (including B. fragilis*). *Efficacy for this organism in this organ system was studied in fewer than 10 infections. While Ampicillin and Sulbactam for Injection is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with Ampicillin and Sulbactam for Injection due to its ampicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and beta-lactamase producing organisms susceptible to Ampicillin and Sulbactam for Injection should not require the addition of another antibacterial.Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to Ampicillin and Sulbactam for Injection.Therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above in the indicated organ systems. Once the results are known, therapy should be adjusted if appropriate.To reduce the development of drug-resistant bacteria and maintain effectiveness of Ampicillin and Sulbactam for Injection and other antibacterial drugs, Ampicillin and Sulbactam for Injection should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Regulatory & Marketing

Labeler Name
Onesource Specialty Pharma Limited
Product Type
Human Prescription Drug
FDA Application #
ANDA202197
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
05-01-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 83270-308-01 identifies a specific commercial package of 1 bottle in 1 carton / 15 g in 1 bottle of Ampicillin Sodium And Sulbactam Sodium, a human prescription drug labeled by Onesource Specialty Pharma Limited. This injection, powder, for solution is formulated for intramuscular; intravenous use and contains ampicillin sodium; sulbactam sodium as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Onesource Specialty Pharma Limited on May 01, 2025. The current certification is valid through December 31, 2026.

How is this Onesource Specialty Pharma Limited product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 83270030801. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
83270-308-01
11-Digit CMS (5-4-2)
83270-0308-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.